Related Experiment Video
Updated: Sep 14, 2025
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Deciphering the differential impact of CDK4 mutations on abemaciclib binding in oral squamous cell carcinoma: a
1Department of Stomatology, Nantong Integrated Traditional Chinese and Western Medicine Hospital, Nantong, Jiangsu, China.
Background:
Precisi on medicine is an emerging approach for disease treatment and its major challenge is the development of drug resistance. Understanding the role of specific mutations in drug resistance is crucial for the development of next-generation therapeutics.
Methodology:
Cyclin-dependent kinase-4 (CDK4) is a pivotal regulator of the cell cycle, with mutations implicated in oncogenesis in oral squamous cell carcinoma (OSCC). Abemaciclib is one of the major reference drugs designed to inhibit CDK4. This study employs a biophysical approach to examine the binding dynamics between abemaciclib, a selective CDK4 inhibitor, and both wild-type and mutant forms of CDK4. Focusing on the hinge loop region, which includes mutations D99G, R101M, T102K, and P110L, molecular dynamics simulations reveal differential effects on drug binding stability.
Results:
Findings indicate that while D99G and R101M mutants sustain stable drug interactions, the T102K and P110L mutants exhibit significantly weakened binding, evidenced by altered free energy landscapes, increased structural fluctuations, and diminished hydrogen bond interactions. These findings suggest that patients with CDK4 mutations, particularly T102K and P110L, may exhibit resistance to abemaciclib, necessitating the development of alternative therapeutic strategies.
Conclusion:
Further studies are essentially required to enhance the precision of cancer treatment, ensuring that each patient receives the most effective therapy based on their unique genetic makeup.
Insights
Drug resistance in oral cancer is a challenge. CDK4 mutations like T102K and P110L weaken abemaciclib binding, suggesting potential treatment resistance and the need for new therapies.
Area of Science:
- Molecular biology
- Pharmacology
- Oncology
Background:
- Precision medicine aims to tailor treatments but faces drug resistance.
- Understanding mutations driving drug resistance is key for developing advanced therapeutics.
- Cyclin-dependent kinase-4 (CDK4) mutations are linked to oral squamous cell carcinoma (OSCC) development.
Purpose of the Study:
- To investigate the biophysical binding dynamics of the CDK4 inhibitor abemaciclib with wild-type and mutant CDK4.
- To identify specific CDK4 mutations affecting abemaciclib's binding stability and efficacy.
Main Methods:
- Employed molecular dynamics simulations to analyze binding interactions.
- Focused on the CDK4 hinge loop region, examining mutations D99G, R101M, T102K, and P110L.
- Assessed changes in free energy landscapes, structural fluctuations, and hydrogen bond interactions.
Main Results:
- CDK4 mutations D99G and R101M maintained stable abemaciclib interactions.
- Mutations T102K and P110L significantly reduced abemaciclib binding stability.
- Weakened binding correlated with altered energy landscapes, increased fluctuations, and fewer hydrogen bonds.
Conclusions:
- Patients with T102K and P110L CDK4 mutations may show resistance to abemaciclib.
- Alternative therapeutic strategies are needed for patients with these specific mutations.
- Further research is crucial for personalized cancer treatment based on genetic profiles.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...